Condition
Rabies Virus Infection
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
Early P 1 (1)
P 2 (1)
Trial Status
Unknown1
Not Yet Recruiting1
Terminated1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05382650Terminated
Survey of Human Rabies Immune Globulin Safety in Children
NCT06548139Phase 2Not Yet RecruitingPrimary
Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials
NCT05832073Early Phase 1UnknownPrimary
Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1
NCT04213950Not ApplicableCompleted
Improving Adherence to Rabies PEP Guideline Recommendations
Showing all 4 trials